Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence

Summary

This open-label extension study, for subjects from the G201002 study, will provide additional long-term safety and tolerability data for GTx-024. All subjects in this study will receive GTx-024 3 mg orally, once daily.

Timeline

Start

2018-06-28

Primary completion

2018-09-21

Completion

2018-09-21

Outcome

Outcome not reported

Stopped: “Development of investigational product was halted.”

Drugs

Indications